<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version v40?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-307</article-id><article-id pub-id-type="pmid">19723334</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Histological evaluation of AMPK signalling in primary breast cancer</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Hadad</surname><given-names>Sirwan M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.hadad@dundee.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Baker</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>l.baker@dundee.ac.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Quinlan</surname><given-names>Philip R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>p.quinlan@dundee.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Robertson</surname><given-names>Katherine E</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>k.e.robertson@dundee.ac.uk</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Bray</surname><given-names>Susan E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s.e.bray@dundee.ac.uk</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Thomson</surname><given-names>George</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>grorge.thomson@nhs.net</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Kellock</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>d.b.kellock@dundee.ac.uk</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Jordan</surname><given-names>Lee B</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lee.jordan@nhs.net</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Purdie</surname><given-names>Colin A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Colin.purdie@nhs.net</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Hardie</surname><given-names>David G</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>d.g.hardie@dundee.ac.uk</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Fleming</surname><given-names>Stewart</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>s.fleming@dundee.ac.uk</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Thompson</surname><given-names>Alastair M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>a.m.thompson@dundee.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, Dundee, UK</aff><aff id="I2"><label>2</label>Department of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee, UK</aff><aff id="I3"><label>3</label>Division of Molecular Physiology, College of Life Sciences, University of Dundee, Dundee, UK</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>1</day><month>9</month><year>2009</year></pub-date><volume>9</volume><fpage>307</fpage><lpage>307</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/307"/><history><date date-type="received"><day>10</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Hadad et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Hadad et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Hadad M Sirwan s.hadad@dundee.ac.uk </dc:author><dc:title> Histological evaluation of AMPK signalling in primary breast cancer </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 307-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;307&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>AMP-activated protein kinase (AMPK) acts as a cellular fuel gauge that responds to energy stress by suppressing cell growth and biosynthetic processes, thus ensuring that energy-consuming processes proceed only if there are sufficient metabolic resources. Malfunction of the AMPK pathway may allow cancer cells to undergo uncontrolled proliferation irrespective of their molecular energy levels. The aim of this study was to examine the state of AMPK phosphorylation histologically in primary breast cancer in relation to clinical and pathological parameters.</p></sec><sec sec-type="methods"><title>Methods</title><p>Immunohistochemistry was performed using antibodies to phospho-AMPK (pAMPK), phospho-Acetyl Co-A Carboxylase (pACC) an established target for AMPK, HER2, ER&#x003b1;, and Ki67 on Tissue Micro-Array (TMA) slides of two cohorts of 117 and 237 primary breast cancers. The quick score method was used for scoring and patterns of protein expression were compared with clinical and pathological data, including a minimum 5 years follow up.</p></sec><sec><title>Results</title><p>Reduced signal, compared with the strong expression in normal breast epithelium, using a pAMPK antibody was demonstrated in 101/113 (89.4%) and 217/236 (91.9%) of two cohorts of patients. pACC was significantly associated with pAMPK expression (p = 0.007 &#x00026; p = 0.014 respectively). For both cohorts, reduced pAMPK signal was significantly associated with higher histological grade (p = 0.010 &#x00026; p = 0.021 respectively) and axillary node metastasis (p = 0.061 &#x00026; p = 0.039 respectively). No significant association was found between pAMPK and any of HER2, ER&#x003b1;, or Ki67 expression, disease-free survival or overall survival.</p></sec><sec><title>Conclusion</title><p>This study extends <italic>in vitro </italic>evidence through immunohistochemistry to confirm that AMPK is dysfunctional in primary breast cancer. Reduced signalling via the AMPK pathway, and the inverse relationship with histological grade and axillary node metastasis, suggests that AMPK re-activation could have therapeutic potential in breast cancer.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>AMP-activated protein kinase (AMPK) is an intracellular energy-sensing kinase that is inactive unless it has been phosphorylated by upstream kinases at a specific threonine residue (Thr-172) within the kinase domain. Phosphorylation at Thr-172 and consequent activation occurs in response to metabolic stresses that deplete cellular energy levels and thus increase the AMP/ATP ratio [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Activation of AMPK can be assessed using a phosphospecific antibody (anti-pAMPK) that recognizes either catalytic subunit isoform (&#x003b1;1 or &#x003b1;2), but only when phosphorylated at Thr-172. AMPK is proposed as a "fuel gauge" that monitors changes in the energy status of cells [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. It is activated by metabolic stresses that inhibit ATP production such as glucose deprivation [<xref ref-type="bibr" rid="B4">4</xref>], ischaemia [<xref ref-type="bibr" rid="B5">5</xref>], or hypoxia [<xref ref-type="bibr" rid="B6">6</xref>], or by stresses that accelerate ATP consumption such as contraction in skeletal muscle [<xref ref-type="bibr" rid="B7">7</xref>]. Once activated, AMPK down-regulates energy-consuming processes, including cell proliferation, thus ensuring that these processes only proceed if there are sufficient metabolic resources available [<xref ref-type="bibr" rid="B8">8</xref>]. AMPK switches on catabolic pathways that generate ATP, while switching off biosynthetic pathways and other processes that consume ATP, and hence has a key role in maintaining energy balance both at the single cell and the whole body levels [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>One direct downstream target of AMPK is acetyl-Coenzyme A carboxylase (ACC). In its active, de-phosphorylated form, ACC catalyzes the conversion of acetyl-CoA to malonyl-CoA in the de novo lipid synthesis pathway [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. When it is inactivated by phosphorylation, a decrease in malonyl-CoA occurs, thereby increasing the mitochondrial import and oxidation of long chain fatty acids (LCFAs), resulting in the generation of ATP [<xref ref-type="bibr" rid="B12">12</xref>]. ACC exists as two isoforms, ACC1/a and ACC2/b, with ACC1 being thought to produce the pool of malonyl-CoA involved in fatty acid synthesis, while ACC2 is thought to produce the mitochondrial pool that regulates fatty acid oxidation [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. AMPK phosphorylates ACC1 at multiple residues, although phosphorylation at a single serine (Ser-79 in rat and Ser-80 in human ACC1) accounts for the resulting inactivation [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. AMPK also inactivates ACC2 [<xref ref-type="bibr" rid="B17">17</xref>] via phosphorylation at the site equivalent to Ser-79 on ACC1 (Ser-221 in human ACC2). A phosphospecific antibody (anti-pACC) recognizes both ACC1 and ACC2 phosphorylated at these sites, and is a widely used marker for AMPK activation. In isolated hepatocytes from AMPK-&#x003b1;1<sup>-/- </sup>and -&#x003b1;2<sup>-/- </sup>double knockout mice, the signal obtained using this antibody is completely lost, showing that AMPK is responsible for phosphorylation at these sites [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>There is a large body of evidence to support the link between metabolic disorders, such as obesity and type 2 diabetes, and dysfunctional lipid and energy metabolism causing increases in circulatory and intracellular fatty acids [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. High levels of fatty acids are toxic to cells and may cause deleterious metabolic abnormalities [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. These unwanted effects could be prevented by activation of AMPK and consequent inactivation of ACC2 in peripheral tissues, leading to an increase in fatty acid oxidation [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. In addition many cancer cells, including many breast tumours, exhibit a markedly increased rate of fatty acid synthesis [<xref ref-type="bibr" rid="B20">20</xref>]. Some breast tumours express high levels of fatty acid synthase (FAS), a key enzyme for fatty acid biosynthesis [<xref ref-type="bibr" rid="B21">21</xref>]. FAS is up-regulated in about 50% of breast cancers, is an indicator of poor prognosis, and is associated with the HER2 oncogene [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. The drug Orlistat (Xenical&#x02122;), which was developed as an inhibitor of gastric and pancreatic lipases and has been approved for weight loss by the FDA, blocks breast cancer cell cycle progression, promotes apoptotic cell death, and transcriptional repression of the HER2 oncogene [<xref ref-type="bibr" rid="B25">25</xref>]. In addition to these potentially beneficial effects of AMPK activation on lipid metabolism, AMPK would also be expected to directly inhibit cell growth and proliferation. The major kinase that phosphorylates Thr-172 on AMPK has been identified to be the tumour suppressor kinase, LKB1 [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Although LKB1 is also the upstream kinase for a family of twelve additional AMPK-related kinases [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>], many of the tumour suppressor effects of LKB1 are likely to be mediated by AMPK. For example, AMPK activation causes a G1-S phase cell cycle arrest [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>], while it also inhibits cell growth by switching off the target-of-rapamycin (TOR) pathway [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Consistent with the idea that AMPK activation might inhibit growth of tumour cells were findings that the oral anti-diabetic drug, metformin, inhibits proliferation of epithelial cells derived from breast, prostate and ovarian cancers, an effect that requires both LKB1 and AMPK [<xref ref-type="bibr" rid="B34">34</xref>]. These findings may be clinically relevant, because epidemiological studies show an association between a lower incidence of cancer, including breast cancer, and metformin usage in diabetic patients [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>].</p><p>Despite growing evidence in this arena, little is known about the state of phosphorylation of AMPK, and its downstream target ACC, in human breast cancers. Since malignant cells are likely to have an increased energy demand and may also experience hypoxia and other metabolic stresses, one might speculate that AMPK signalling would be activated. The objective of the present study was to evaluate the status of phosphorylation of AMPK and ACC signalling in human primary breast cancer using immunohistochemistry, and to correlate this with the clinical and pathological characteristics of the tumours.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>A total of 354 primary human breast cancer specimens were used in this study from two cohorts of patients. The first cohort comprised 117 of the pre- and post-menopausal women (aged 34 - 76; median 51 years) with primary breast cancer who participated in the Adjuvant Breast Cancer (ABC) clinical trial from 1992 to 2000 at a single recruiting centre (NHS Tayside) [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>The second cohort of patients comprised 237 unselected pre- and post-menopausal women (aged 28 - 89; median 62 years) with primary, previously untreated breast cancer who were seen and treated at Tayside University Hospitals, Scotland, from 1997 to 2002. Informed consent was obtained from each patient prior to tissue acquisition. Tumour samples from these patients were constructed on tissue microarray (TMA) slides as described below. Ethics approval was given by the Tayside Research and Ethics committee (Ref. 07/S1402/90).</p></sec><sec><title>TMA construction</title><p>A TMA containing up to six 0.6 mm diameter cores of invasive tumours and normal breast tissue from the same patients was constructed using a manual tissue arrayer (Beecher Instruments Inc., Sun Prairie, WI, USA). Briefly, haematoxylin and eosin (H&#x00026;E) stained sections of normal and tumour tissues were reviewed by a single pathologist. Areas suitable for inclusion in the TMA were marked on the slide. Marked slides were matched to their corresponding wax blocks (the donor blocks). The areas of interest were marked on the wax blocks using a marker pen and 0.6 mm diameter cores of tumour or normal breast tissue were removed and inserted into a pre-cored hole in a recipient paraffin block. Cores were inserted in a grid arrangement. Normal breast tissue cores were constructed alongside the cancerous cores for every patient. Four micron TMA sections were cut, mounted onto poly-L-lysine coated glass slides (VWR International Ltd., Lutterworth, UK), and dried for 1 hour at 60&#x000b0;C before being de-paraffinised in Histoclear (National Diagnostics, Hessle, UK) and xylene, then run through a graded series of alcohol and rehydrated under running water.</p></sec><sec><title>Immunohistochemistry (IHC)</title><p>pAMPK (Thr-172) monoclonal antibody and pACC (Ser-79) were purchased from Cell Signaling Technology. MIB1 (Anti-Ki67) and anti-HER2 monoclonal antibodies were purchased from Novocastra. Optimal staining conditions such as epitope unmasking, antibody titre, and incubation and visualisation method were validated on conventional whole tissue sections and TMA fragments. Positive controls included normal spleen and breast epithelium for pAMPK and pACC, and breast cancer samples of established ER, HER2 and Ki67. Citric acid buffer, pH 6.0 (10 mM) was used as standard microwave-based antigen retrieval method for all proteins except for pACC. Sections were immersed in 10 mM Citric acid buffer, pH 6.0 and subjected to microwave in a pressure vessel for 15 min before then processed on a DAKO autostainer using Vectastatin<sup>&#x000ae; </sup>ABC kits (Vector Labs, Peterborough, UK) according to the manufacturer's protocol. Ethylene diaminetetraacetic acid disodium salt dihydrate (EDTA) (Sigma product E-5134) for 45 minutes at 94&#x000b0;C was used for pACC antigen retrieval. Sections were blocked by either normal goat, horse or rabbit serum containing 10% (v/v) from stock avidin solution (Vector Labs) for 20 min followed by incubation with primary antibody including 10% (v/v) from stock biotin solution (Vector Labs) for 1 hour to reduce non-specific background staining. Following incubation with the specific primary antibodies, sections were incubated with either biotinylated anti-rabbit, anti-sheep, or anti-mouse antibody for 30 min followed by Vectastain<sup>&#x000ae; </sup>Elite ABC reagent for another 30 min. Liquid diaminobenzidine (DAB; Dako) was used as a chromogenic agent for 5 min and sections were counter-stained with Mayer's haematoxylin. In between each immunostaining step, slides were washed briefly in Tris buffered saline (TBS) buffer, pH 7.6.</p></sec><sec><title>Scoring</title><p>Primary TMA scoring was performed by a single author (SMH), verified by an experienced consultant pathologist (SF) and where needed by a specialist breast pathologist (LJ or CAP) using a Nikon Eclipse E600 light microscope with DXM 1200 digital camera and Eclipse-Net software, and Virtual Microscopy in the form of Aperio Technologies, ScanScope XT and Spectrum Plus using TMA software version 9.1. Cores were scored at a magnification of &#x000d7;40 (Figure <xref ref-type="fig" rid="F1">1</xref>). Any discrepancies were resolved by subsequent consultation. HER2 immunostaining of cores containing tumour were evaluated as 0, 1+, 2+ and 3+ according to the US FDA-approved scoring guidelines for the Hercep Test [52]: non-specific membrane staining = 0, membrane or cytoplasmic staining in &#x0003c;10% of cells = 1+, specific membrane staining in &#x0003e;10% of cells = 2+, and strong specific staining in majority of cells = 3+. HER2 amplification was confirmed for 2+ and 3+ tumours using FISH (Fluorescence In Situ Hybridization). For Ki67 proliferation index (the fraction of proliferating cells), ER&#x003b1;, pAMPK and pACC antibody staining of cores containing tumour were assessed using a scoring system based on the Quick Score Method [<xref ref-type="bibr" rid="B35">35</xref>]. Immuno-reactivity scored semi-quantitatively for both the intensity and the proportion of cells staining: intensity was given scores 0-3 (no staining = 0; light staining = 1; moderate staining = 2; strong staining = 3) and proportion was given scores 1-6 (0-4% = 1; 5-20% = 2; 21-40% = 3; 41-60% = 4; 61-80% = 5; 81-100% = 6). The two scores were then multiplied to obtain the final result of 0 - 18. Cores from normal spleen and normal breast tissue were used as control on each slide.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Strong staining of AMPK in normal breast lobular unit (A) compared to its light staining in tumour cells (B)</bold><bold>, examples of a positive Ki67 (C) and HER2 (D).</bold></p></caption><graphic xlink:href="1471-2407-9-307-1"/></fig></sec><sec><title>Statistics</title><p>All analyses were performed using Microsoft Excel 2002 SP3 (Microsoft Corporation) and Minitab Release 14.13 (Minitab Inc.). Appropriate choice of <italic>&#x003c7;</italic><sup>2 </sup>for trend and Fisher's Exact Test (FET) were used for significance of expression, and non-parametric survival plots used the Kaplan-Meier method. When grouping of scores was required for a statistical method, such as Fisher's Exact Test, pAMPK scores were grouped as scores 3 versus scores 0 - 2, chosen because normal breast epithelial cell staining had similar strong staining as the tumour cells scored 3. The pAMPK results were based on comparing strongly positive AMPK signalling in tumour cells that scored 3 to scores of 0 - 2. For Ki67, scores 0 - 2 were grouped against 3 - 6. For HER2, scores 0 - 1 versus 2 - 3 with FISH verification of the amplification of the latter group; while for ER&#x003b1;, scores 0 - 3 (negative) versus 4 - 18 (positive) was chosen [<xref ref-type="bibr" rid="B38">38</xref>]. However, where <italic>&#x003c7;</italic><sup>2 </sup>for trend was used, the scores were not dichotomised. The null hypothesis was rejected at an &#x003b1; level of 10% (p &#x02264; 0.10), and observations considered to be marginal (i.e. of scientific interest and worthy of further investigation) for an &#x003b1; level between 5% and 10% (p &#x02264; 0.10) and significant at 5% (p &#x02264; 0.05).</p></sec></sec><sec><title>Results</title><p>For the first cohort of the 117 patients, 104 (88.9%) were infiltrating ductal carcinoma, 3 (2.6%) infiltrating lobular and 10 (8.5%) mixed or other types. All cases were successfully scored for Ki67 and HER2; 3/117 (2.6%) for pACC, and 4/117 (3.4%) for pAMPK were not evaluable on the TMAs.</p><p>In the second cohort of 237 patients, 197 (83.1%) were infiltrating ductal carcinoma, 16 (6.7%) infiltrating lobular carcinoma, and 34 (14.3%) were mixed and other types. One case (1/237 (0.4%)) was excluded from scoring for pAMPK and 19/237 (8%) for pACC were not evaluable (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinico-pathological characteristics of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Parameter</bold></td><td align="center"><bold>Cohort 1 [n (%)]</bold></td><td align="center"><bold>Cohort 2 [n (%)]</bold></td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>N</italic></bold></td><td align="center">117</td><td align="center">237</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Menopausal status at diagnosis</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Pre- and peri-menopausal</td><td align="center">62 (53)</td><td align="center">56 (24)</td><td align="center">&#x0003c; 0.001*</td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Post-menopausal</td><td align="center">55 (47)</td><td align="center">181 (76)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Age (years)</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Median (range)</td><td align="center">51 (34-76)</td><td align="center">62 (28-89)</td><td align="center">&#x0003c; 0.001<sup>~</sup></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Tumour size (cm)</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;&#x02264; 2</td><td align="center">61 (57)</td><td align="center">88 (37)</td><td align="center">&#x0003c; 0.001*</td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;&#x0003e; 2</td><td align="center">46 (43)</td><td align="center">148 (63)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Number of positive lymph nodes</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;0</td><td align="center">48 (41)</td><td align="center">127 (54)</td><td align="center">0.032*<sup>&#x02020;</sup><break/>0.540*<sup>&#x02021;</sup></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;1-3</td><td align="center">48 (41)</td><td align="center">74 (31)</td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;&#x0003e; 3</td><td align="center">21 (18)</td><td align="center">36 (15)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Histological grade</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;1</td><td align="center">12 (10)</td><td align="center">34 (14)</td><td align="center">0.399*<sup>&#x02020;</sup><break/>0.425*<sup>&#x02021;</sup></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;2</td><td align="center">43 (38)</td><td align="center">91 (39)</td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;3</td><td align="center">59 (52)</td><td align="center">110 (47)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Adjuvant therapy</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">&#x02003;Endocrine therapy</td><td align="center">18 (16)</td><td align="center">59 (27)</td><td align="center">N/A</td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Chemotherapy and/or Radiotherapy</td><td align="center">0 (0)</td><td align="center">54 (24)</td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Endocrine + Chemotherapy</td><td align="center">12 (10)</td><td align="center">10 (4)</td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Endocrine + Radiotherapy</td><td align="center">45 (38)</td><td align="center">70 (31)</td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Endocrine + Chemo + Radiotherapy</td><td align="center">42 (36)</td><td align="center">31 (14)</td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><italic>Follow up (months)</italic></bold></td><td></td><td></td><td></td></tr><tr><td colspan="3"><hr></hr></td><td></td></tr><tr><td align="left">&#x02003;Median (range)</td><td align="center">73 (9-122)</td><td align="center">60 (1-120)</td><td align="center">&#x0003c; 0.001<sup>~</sup></td></tr></tbody></table><table-wrap-foot><p>Notes: *2-sided Fisher's Exact Test; <sup>~ </sup>Mann-Whitney U-test; <sup>&#x02020;</sup>first row <italic>versus </italic>summation of all other rows; <sup>&#x02021;</sup>last row <italic>versus </italic>summation of all other rows.</p></table-wrap-foot></table-wrap><p>Cytoplasmic staining was seen for pAMPK and, as expected, nuclear staining for Ki67 and ER&#x003b1;; combined cell membrane and cytoplasm staining for pACC; cell membrane strongly and cytoplasm lightly for HER2. Normal breast epithelium did not stain for Ki67, HER2 or pACC; however strong staining of normal breast epithelial cytoplasm was observed for pAMPK (Figure <xref ref-type="fig" rid="F1">1A</xref>).</p><p>Reduced AMPK phosphorylation signal (scores 0 - 2) was seen in the vast majority of the breast cancer specimens (101/113 [89.4%] and 217/236 [91.9%] of the first and second cohort respectively), as light staining of the cytoplasm (Figure <xref ref-type="fig" rid="F1">1B</xref>), compared to strong expression in normal breast epithelium (score 3). A significant positive association was seen between pAMPK and pACC signals (FET: p = 0.007 and 0.014 respectively). Reduced AMPK phosphorylation signal was associated with higher histological grade (<italic>&#x003c7;</italic><sup>2 </sup>for trend = 6.644, df = 1, p = 0.010; and <italic>&#x003c7;</italic><sup>2 </sup>for trend = 5.291, df = 1, p = 0.021). AMPK phosphorylation signal reduction was also associated with axillary node metastasis (FET: p = 0.061 and 0.039 respectively) (Table <xref ref-type="table" rid="T2">2</xref> and additional file <xref ref-type="supplementary-material" rid="S1">1</xref>)</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>The association between AMPK and all clinico-pathological and immunohistochemical data</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="3"><bold>Cohort 1</bold></td><td align="center" colspan="3"><bold>Cohort 2</bold></td></tr></thead><tbody><tr><td align="left"><bold>Parameter</bold></td><td></td><td align="center"><bold>Positive</bold></td><td align="center"><bold>Negative</bold></td><td align="center"><bold>P</bold></td><td align="center"><bold>Positive</bold></td><td align="center"><bold>Negative</bold></td><td align="center"><bold>P</bold></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>HER2</bold></td><td align="left">Positive</td><td align="center">0</td><td align="center">14</td><td align="center">NS</td><td align="center">0</td><td align="center">13</td><td align="center">NS</td></tr><tr><td></td><td align="left">Negative</td><td align="center">12</td><td align="center">87</td><td></td><td align="center">3</td><td align="center">95</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>Ki67</bold></td><td align="left">Positive</td><td align="center">4</td><td align="center">36</td><td align="center">NS</td><td align="center">7</td><td align="center">95</td><td align="center">NS</td></tr><tr><td></td><td align="left">Negative</td><td align="center">8</td><td align="center">65</td><td></td><td align="center">11</td><td align="center">111</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>ACC</bold></td><td align="left">Positive</td><td align="center">7</td><td align="center">20</td><td align="center">0.007</td><td align="center">7</td><td align="center">29</td><td align="center">0.014</td></tr><tr><td></td><td align="left">Negative</td><td align="center">5</td><td align="center">81</td><td></td><td align="center">12</td><td align="center">186</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>ER&#x003b1;</bold></td><td align="left">Positive</td><td align="center">9</td><td align="center">61</td><td align="center">NS</td><td align="center">12</td><td align="center">157</td><td align="center">NS</td></tr><tr><td></td><td align="left">Negative</td><td align="center">3</td><td align="center">38</td><td></td><td align="center">7</td><td align="center">59</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>Tumour size (cm)</bold></td><td align="left">&#x02264; 2</td><td align="center">7</td><td align="center">51</td><td align="center">NS</td><td align="center">9</td><td align="center">79</td><td align="center">NS</td></tr><tr><td></td><td align="left">&#x0003e; 2</td><td align="center">2</td><td align="center">43</td><td></td><td align="center">10</td><td align="center">138</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>Positive axillary nodes</bold></td><td align="left">0</td><td align="center">8</td><td align="center">39</td><td align="center">0.021</td><td align="center">15</td><td align="center">111</td><td align="center">0.087</td></tr><tr><td></td><td align="left">1-3</td><td align="center">2</td><td align="center">44</td><td></td><td align="center">2</td><td align="center">71</td><td></td></tr><tr><td></td><td align="left">&#x0003e; 3</td><td align="center">0</td><td align="center">12</td><td></td><td align="center">2</td><td align="center">35</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>Histological grade</bold></td><td align="left">1</td><td align="center">5</td><td align="center">7</td><td align="center">0.010</td><td align="center">6</td><td align="center">57</td><td align="center">0.021</td></tr><tr><td></td><td align="left">2</td><td align="center">2</td><td align="center">39</td><td></td><td align="center">7</td><td align="center">81</td><td></td></tr><tr><td></td><td align="left">3</td><td align="center">4</td><td align="center">53</td><td></td><td align="center">5</td><td align="center">99</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>KM overall survival</bold></td><td align="left">Alive</td><td align="center">11</td><td align="center">73</td><td align="center">NS</td><td align="center">11</td><td align="center">154</td><td align="center">NS</td></tr><tr><td></td><td align="left">Dead</td><td align="center">1</td><td align="center">28</td><td></td><td align="center">4</td><td align="center">35</td><td></td></tr></tbody></table></table-wrap><p>Ki67 expression (Figure <xref ref-type="fig" rid="F1">1C</xref>) was negatively associated with ER status (FET: p = 0.002 and p &#x0003c; 0.001 respectively) (see additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). It was also associated with higher grade tumours (FET: p &#x0003c; 0.001 in both cohorts), increased tumour recurrence (FET: p = 0.041 and 0.005, Relative Risk (RR) = 1.89 and 1.59, Odds Ratio (OR) = 2.39 and 2.47, respectively) and lower overall survival (Kaplan-Meier Log Rank Test: p = 0.023 and 0.015, RR = 1.62 and 2.13, OR = 2.29 and 23.39, respectively) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Kaplan-Meier Survival analysis correlating Ki67 expression to overall survival in both cohorts (p = 0.023 and p = 0.015 respectively)</bold>.</p></caption><graphic xlink:href="1471-2407-9-307-2"/></fig><p>HER2 amplification, found in 11.9% (14/117) and 13.9% (32/230) of patients respectively (Figure <xref ref-type="fig" rid="F1">1D</xref>), was significantly associated with Ki67 expression (FET: p = 0.006 and 0.021 respectively), higher histological grade (FET: p = 0.073 and &#x0003c; 0.001 respectively), and inversely with ER status (FET: p = 0.006 and 0.001 respectively). HER2 positive patients had increased recurrence (FET: p = 0.027 and 0.001, RR = 1.72 and 1.96, OR = 3.75 and 7.2, respectively); and lower overall survival (Kaplan-Meier Log Rank Test: p &#x0003c; 0.001 and 0.075, RR = 2.81 and 1.99, OR = 5.19 and 2.3, respectively) (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Kaplan-Meier survival analysis correlating HER2 status to overall survival in both cohorts (p &#x0003c; 0.001 and = 0.075 respectively)</bold>.</p></caption><graphic xlink:href="1471-2407-9-307-3"/></fig><p>ER positive tumours, identified in 62.6% (72/115) and 73% (173/237) of patients respectively, were associated with HER2 negative (FET: p = 0.006 and 0.001 respectively), low Ki67 expression (FET: p = 0.002 and &#x0003c; 0.001 respectively), lower grade tumours (FET: p = 0.029 and &#x0003c; 0.001 respectively), and lower disease recurrence (FET: p = 0.033 and &#x0003c; 0.001, RR = 1.41 and 2.75, OR = 2.33 and 4.36, respectively). In the second cohort of patients, ER positive patients also lived longer (Kaplan-Meier Log Rank Test: p &#x0003c; 0.001, RR = 1.44, OR = 5.81) (Figure <xref ref-type="fig" rid="F4">4</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Kaplan-Meier Survival Curve correlating ER status to overall survival in both cohorts (p = 0.102 and &#x0003c; 0.001 respectively)</bold>.</p></caption><graphic xlink:href="1471-2407-9-307-4"/></fig></sec><sec><title>Discussion</title><p>Malignant transformation of cells is characterized by insensitivity to growth-inhibitory signals, unlimited replicative potential, angiogenesis, tissue invasion and metastasis [<xref ref-type="bibr" rid="B38">38</xref>]. Despite the physiological stresses in cancer cells, and the associated hypoxia in both primary and metastatic cancer [<xref ref-type="bibr" rid="B39">39</xref>], malignant cells continue to proliferate and invade. These hallmark characteristics of cancer raise the question of whether dysfunction of AMPK could have a role in malignancy. The aim of this study was to evaluate phosphorylation of AMPK and ACC as markers of AMPK signalling in human breast cancer in relation to clinical and pathological data.</p><p>The two cohorts of patients were representative of previously reported breast cancer populations as exemplified by the associations between HER2 amplification, Ki67 expression, ER negative cancers, higher histological grade, Ki67 labelling index [<xref ref-type="bibr" rid="B40">40</xref>] and higher disease recurrence and lower overall survival. The significant differences in menopausal status, age, tumour size and node status between the two cohorts (Table <xref ref-type="table" rid="T1">1</xref>) perhaps emphasizes the consistent trends and significant associations of AMPK signalling with node status and tumour grade respectively (Table <xref ref-type="table" rid="T2">2</xref>). Further possible caveats include the use of IHC rather than western blotting to assess the signalling pathways, although the distribution of signalling in normal and cancerous tissues on IHC allowed localisation of the proteins.</p><p>Despite the high energy consuming processes of uncontrolled cellular proliferation in breast cancer, the histological evidence suggests that AMPK does not seem to respond in primary breast cancer. In contrast, normal breast epithelium demonstrated appropriate AMPK staining, but as expected for a quiescent epithelium no activation of ACC. Reduced signalling of AMPK phosphorylation in the majority of the breast cancer specimens (89.4% in the first and 91.9% in the second cohort) compared to strong expression in normal breast epithelial cells, and the inverse relationship between staining with histological grade and node status supports the current view that activating this energy-sensing enzyme may be a potential therapeutic avenue in breast cancer [<xref ref-type="bibr" rid="B8">8</xref>]. Lower tumour growth fraction, assessed by lower Ki67 proliferation index in patients with activated ACC, a downstream target of AMPK, is consistent with <italic>in vitro </italic>evidence that AMPK activation leads to reduced proliferation [<xref ref-type="bibr" rid="B41">41</xref>] and growth inhibition in epithelial cells [<xref ref-type="bibr" rid="B34">34</xref>], also associated with decreased mTOR signalling [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. AMPK activation is known to lead to inhibition of the mTOR pathway [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>] through phosphorylation of TSC2 [<xref ref-type="bibr" rid="B32">32</xref>] and Raptor [<xref ref-type="bibr" rid="B33">33</xref>]. Activation of AMPK also directly limits translational initiation and protein synthesis through inhibition of translation elongation factor 2 (EF2) [<xref ref-type="bibr" rid="B46">46</xref>]. In this study we have focused on histological evidence for AMPK phosphorylation and its direct downstream target, ACC, as markers of AMPK activation, and have correlated them with the functionally important biological markers of breast cancer: ER, Ki67 and HER2.</p></sec><sec><title>Conclusion</title><p>In conclusion, the role of AMPK in the mechanism of action of metformin [<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B49">49</xref>], evidence in support of a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer [<xref ref-type="bibr" rid="B50">50</xref>], and the reduced risk of cancer in patients with type 2 diabetes taking metformin compared with those on other medications such as sulphonylureas [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B51">51</xref>], are all indicative of the need to explore this relationship and its potential to discover a novel targeted therapy in breast cancer. AMPK activation is a possible therapeutic target for cancers, since AMPK inhibits mTOR signalling, which in turn inhibit tumour growth <italic>in vitro </italic>and metastasis in experimental animal models [<xref ref-type="bibr" rid="B20">20</xref>]. The data presented here, the first immunohistochemical evidence of AMPK dysfunction in primary breast cancer supports further laboratory and clinical research targeting AMPK by metformin or its analogues in breast cancer.</p></sec><sec><title>Abbreviations</title><p>ACC: Acetyl Coenzyme-A Carboxylase; AMPK: Adeonsine Monophosphate Protein Kinase; ATP: Adensine Triphosphate; DAB: Diaminobenzidine; EDTA: Ethylene Diamine Tetra acetic Acid disodium salt dihydrate; FAS: Fatty Acid Synthase; FET: Fisher's Exact Test; FISH: Fluorescence In Situ Hybridization; IHC: Immunohistochemistry; LCFA: Long Chain Fatty Acids; mTOR: mammalian Target Of Rapamycin; NCRI: National Cancer Research Institute; OR: Odds Ratio; pACC: phospho Acetyl Coenzyme-A Carboxylase; pAMPK: phospho Adenosine Monophosphate Protein Kinase; RR: Relative Risk; TBS: Tris-Buffered Saline.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SMH carried out the TMA staining, immuno-reactivity scoring, initial analysis of the data, and drafted the manuscript. KER and LJ constructed the TMAs. KER wrote the 'method of TMA preparation' part of the materials and methods, and involved in drafting the manuscript. GT and SB guided and helped SMH in TMA staining. LB analysed the data and wrote the statistics section of the manuscript. SF participated rationally in the project design, and with LJ and CAP verified TMA staining and scoring. DGH critically revised the manuscript. AMT substantially contributed to the design of the project, drafting of the manuscript and critically revised it, and gave final approval of the version to be published. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/307/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Supplementary Table</bold>. This table shows the inter-relationship between the biomarkers of interest and all clinico-pathological data.</p></caption><media xlink:href="1471-2407-9-307-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We acknowledge gratefully Breast Cancer Research Scotland and TENOVUS Tayside for funding this project. Grahame Hardie is supported by a Programme Grant from the Wellcome Trust.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Scott</surname><given-names>JW</given-names></name><name><surname>Pan</surname><given-names>DA</given-names></name><name><surname>Hudson</surname><given-names>ER</given-names></name></person-group><article-title>Management of cellular energy by the AMP-activated protein kinase system</article-title><source>FEBS Lett</source><year>2003</year><volume>546</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12829246</pub-id><pub-id pub-id-type="doi">10.1016/S0014-5793(03)00560-X</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>774</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">17712357</pub-id><pub-id pub-id-type="doi">10.1038/nrm2249</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carling</surname><given-names>D</given-names></name></person-group><article-title>AMP-activated protein kinase: balancing the scales</article-title><source>Biochimie</source><year>2005</year><volume>87</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15733742</pub-id><pub-id pub-id-type="doi">10.1016/j.biochi.2004.10.017</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salt</surname><given-names>IP</given-names></name><name><surname>Johnson</surname><given-names>G</given-names></name><name><surname>Ashcroft</surname><given-names>SJ</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release</article-title><source>Biochem J</source><year>1998</year><volume>335</volume><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">9794792</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>N</given-names></name><name><surname>Barr</surname><given-names>AJ</given-names></name><name><surname>Barr</surname><given-names>RL</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Lopaschuk</surname><given-names>GD</given-names></name></person-group><article-title>High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>17513</fpage><lpage>17520</lpage><pub-id pub-id-type="pmid">7615556</pub-id><pub-id pub-id-type="doi">10.1074/jbc.270.29.17513</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marsin</surname><given-names>AS</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Rider</surname><given-names>MH</given-names></name><name><surname>Deprez</surname><given-names>J</given-names></name><name><surname>Beauloye</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>MF</given-names></name><name><surname>Berghe</surname><given-names>G Van den</given-names></name><name><surname>Carling</surname><given-names>D</given-names></name><name><surname>Hue</surname><given-names>L</given-names></name></person-group><article-title>Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia</article-title><source>Curr Biol</source><year>2000</year><volume>10</volume><fpage>1247</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">11069105</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(00)00742-9</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name></person-group><article-title>AMPK: a key sensor of fuel and energy status in skeletal muscle</article-title><source>Physiology (Bethesda)</source><year>2006</year><volume>21</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16443822</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadad</surname><given-names>SM</given-names></name><name><surname>Fleming</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name></person-group><article-title>Targeting AMPK: a new therapeutic opportunity in breast cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2008</year><volume>67</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18343152</pub-id><pub-id pub-id-type="doi">10.1016/j.critrevonc.2008.01.007</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Scott</surname><given-names>JW</given-names></name></person-group><article-title>AMP-activated protein kinase--development of the energy sensor concept</article-title><source>J Physiol</source><year>2006</year><volume>574</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16644800</pub-id><pub-id pub-id-type="doi">10.1113/jphysiol.2006.108944</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruderman</surname><given-names>NB</given-names></name><name><surname>Saha</surname><given-names>AK</given-names></name><name><surname>Vavvas</surname><given-names>D</given-names></name><name><surname>Witters</surname><given-names>LA</given-names></name></person-group><article-title>Malonyl-CoA, fuel sensing, and insulin resistance</article-title><source>Am J Physiol</source><year>1999</year><volume>276</volume><fpage>E1</fpage><lpage>E18</lpage><pub-id pub-id-type="pmid">9886945</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munday</surname><given-names>MR</given-names></name></person-group><article-title>Regulation of mammalian acetyl-CoA carboxylase</article-title><source>Biochem Soc Trans</source><year>2002</year><volume>30</volume><fpage>1059</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">12440972</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGarry</surname><given-names>JD</given-names></name></person-group><article-title>Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">11756317</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.1.7</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu-Elheiga</surname><given-names>L</given-names></name><name><surname>Matzuk</surname><given-names>MM</given-names></name><name><surname>Abo-Hashema</surname><given-names>KA</given-names></name><name><surname>Wakil</surname><given-names>SJ</given-names></name></person-group><article-title>Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2</article-title><source>Science</source><year>2001</year><volume>291</volume><fpage>2613</fpage><lpage>2616</lpage><pub-id pub-id-type="pmid">11283375</pub-id><pub-id pub-id-type="doi">10.1126/science.1056843</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu-Elheiga</surname><given-names>L</given-names></name><name><surname>Brinkley</surname><given-names>WR</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Chirala</surname><given-names>SS</given-names></name><name><surname>Woldegiorgis</surname><given-names>G</given-names></name><name><surname>Wakil</surname><given-names>SJ</given-names></name></person-group><article-title>The subcellular localization of acetyl-CoA carboxylase 2</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>1444</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">10677481</pub-id><pub-id pub-id-type="doi">10.1073/pnas.97.4.1444</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>J</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Broyles</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name></person-group><article-title>Critical phosphorylation sites for acetyl-CoA carboxylase activity</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>22162</fpage><lpage>22168</lpage><pub-id pub-id-type="pmid">7915280</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SP</given-names></name><name><surname>Carling</surname><given-names>D</given-names></name><name><surname>Munday</surname><given-names>MR</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping. Effects of high fat diets</article-title><source>Eur J Biochem</source><year>1992</year><volume>203</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">1346520</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1992.tb16591.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winder</surname><given-names>WW</given-names></name><name><surname>Wilson</surname><given-names>HA</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Rasmussen</surname><given-names>BB</given-names></name><name><surname>Hutber</surname><given-names>CA</given-names></name><name><surname>Call</surname><given-names>GB</given-names></name><name><surname>Clayton</surname><given-names>RD</given-names></name><name><surname>Conley</surname><given-names>LM</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name></person-group><article-title>Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A</article-title><source>J Appl Physiol</source><year>1997</year><volume>82</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">9029219</pub-id><pub-id pub-id-type="doi">10.1063/1.365801</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goransson</surname><given-names>O</given-names></name><name><surname>McBride</surname><given-names>A</given-names></name><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Ross</surname><given-names>FA</given-names></name><name><surname>Shpiro</surname><given-names>N</given-names></name><name><surname>Foretz</surname><given-names>M</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name></person-group><article-title>Mechanism of action of A-76 a valuable tool for activation of AMP-activated protein kinase</article-title><source>J Biol Chem</source><year>9662</year><volume>282</volume><fpage>32549</fpage><lpage>32560</lpage><pub-id pub-id-type="pmid">17855357</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M706536200</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ceddia</surname><given-names>RB</given-names></name></person-group><article-title>Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis</article-title><source>Int J Obes (Lond)</source><year>2005</year><volume>29</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">16030519</pub-id><pub-id pub-id-type="doi">10.1038/sj.ijo.0803025</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motoshima</surname><given-names>H</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>Igata</surname><given-names>M</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name></person-group><article-title>AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer</article-title><source>J Physiol</source><year>2006</year><volume>574</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">16613876</pub-id><pub-id pub-id-type="doi">10.1113/jphysiol.2006.108324</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhajda</surname><given-names>FP</given-names></name><name><surname>Pizer</surname><given-names>ES</given-names></name><name><surname>Li</surname><given-names>JN</given-names></name><name><surname>Mani</surname><given-names>NS</given-names></name><name><surname>Frehywot</surname><given-names>GL</given-names></name><name><surname>Townsend</surname><given-names>CA</given-names></name></person-group><article-title>Synthesis and antitumor activity of an inhibitor of fatty acid synthase</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>3450</fpage><lpage>3454</lpage><pub-id pub-id-type="pmid">10716717</pub-id><pub-id pub-id-type="doi">10.1073/pnas.050582897</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Wong</surname><given-names>SG</given-names></name><name><surname>Levin</surname><given-names>WJ</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>WL</given-names></name></person-group><article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">3798106</pub-id><pub-id pub-id-type="doi">10.1126/science.3798106</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Godolphin</surname><given-names>W</given-names></name><name><surname>Jones</surname><given-names>LA</given-names></name><name><surname>Holt</surname><given-names>JA</given-names></name><name><surname>Wong</surname><given-names>SG</given-names></name><name><surname>Keith</surname><given-names>DE</given-names></name><name><surname>Levin</surname><given-names>WJ</given-names></name><name><surname>Stuart</surname><given-names>SG</given-names></name><name><surname>Udove</surname><given-names>J</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name></person-group><article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title><source>Science</source><year>1989</year><volume>244</volume><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">2470152</pub-id><pub-id pub-id-type="doi">10.1126/science.2470152</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marmor</surname><given-names>MD</given-names></name><name><surname>Skaria</surname><given-names>KB</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>Signal transduction and oncogenesis by ErbB/HER receptors</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>58</volume><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">14967450</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>JA</given-names></name><name><surname>Vellon</surname><given-names>L</given-names></name><name><surname>Lupu</surname><given-names>R</given-names></name></person-group><article-title>Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1253</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">15870086</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdi239</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>JL</given-names></name><name><surname>Mustard</surname><given-names>KJ</given-names></name><name><surname>Udd</surname><given-names>L</given-names></name><name><surname>Makela</surname><given-names>TP</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade</article-title><source>J Biol</source><year>2003</year><volume>2</volume><fpage>28</fpage><pub-id pub-id-type="pmid">14511394</pub-id><pub-id pub-id-type="doi">10.1186/1475-4924-2-28</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>A</given-names></name><name><surname>Johnstone</surname><given-names>SR</given-names></name><name><surname>Dickerson</surname><given-names>K</given-names></name><name><surname>Leiper</surname><given-names>FC</given-names></name><name><surname>Fryer</surname><given-names>LG</given-names></name><name><surname>Neumann</surname><given-names>D</given-names></name><name><surname>Schlattner</surname><given-names>U</given-names></name><name><surname>Wallimann</surname><given-names>T</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Carling</surname><given-names>D</given-names></name></person-group><article-title>LKB1 is the upstream kinase in the AMP-activated protein kinase cascade</article-title><source>Curr Biol</source><year>2003</year><volume>13</volume><fpage>2004</fpage><lpage>2008</lpage><pub-id pub-id-type="pmid">14614828</pub-id><pub-id pub-id-type="doi">10.1016/j.cub.2003.10.031</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaleel</surname><given-names>M</given-names></name><name><surname>McBride</surname><given-names>A</given-names></name><name><surname>Lizcano</surname><given-names>JM</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><name><surname>Morrice</surname><given-names>NA</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><article-title>Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate</article-title><source>FEBS Lett</source><year>2005</year><volume>579</volume><fpage>1417</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">15733851</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2005.01.042</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lizcano</surname><given-names>JM</given-names></name><name><surname>Goransson</surname><given-names>O</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><name><surname>Deak</surname><given-names>M</given-names></name><name><surname>Morrice</surname><given-names>NA</given-names></name><name><surname>Boudeau</surname><given-names>J</given-names></name><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Udd</surname><given-names>L</given-names></name><name><surname>Makela</surname><given-names>TP</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name></person-group><article-title>LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">14976552</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600110</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>K</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Kishimoto</surname><given-names>A</given-names></name><name><surname>Kaminishi</surname><given-names>M</given-names></name><name><surname>Esumi</surname><given-names>H</given-names></name></person-group><article-title>Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>287</volume><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">11554766</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2001.5627</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fogarty</surname><given-names>S</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>C-terminal phosphorylation of LKB1 is not required for regulation of AMPK, BRSK1, BRSK2, or cell cycle arrest</article-title><source>J Biol Chem</source><year>2008</year><volume>284</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18854318</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M806152200</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoki</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>TSC2 mediates cellular energy response to control cell growth and survival</article-title><source>Cell</source><year>2003</year><volume>115</volume><fpage>577</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">14651849</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00929-2</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gwinn</surname><given-names>DM</given-names></name><name><surname>Shackelford</surname><given-names>DB</given-names></name><name><surname>Egan</surname><given-names>DF</given-names></name><name><surname>Mihaylova</surname><given-names>MM</given-names></name><name><surname>Mery</surname><given-names>A</given-names></name><name><surname>Vasquez</surname><given-names>DS</given-names></name><name><surname>Turk</surname><given-names>BE</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name></person-group><article-title>AMPK phosphorylation of raptor mediates a metabolic checkpoint</article-title><source>Mol Cell</source><year>2008</year><volume>30</volume><fpage>214</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">18439900</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2008.03.003</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakikhani</surname><given-names>M</given-names></name><name><surname>Dowling</surname><given-names>R</given-names></name><name><surname>Fantus</surname><given-names>IG</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>10269</fpage><lpage>10273</lpage><pub-id pub-id-type="pmid">17062558</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1500</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>JM</given-names></name><name><surname>Donnelly</surname><given-names>LA</given-names></name><name><surname>Emslie-Smith</surname><given-names>AM</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name></person-group><article-title>Metformin and reduced risk of cancer in diabetic patients</article-title><source>BMJ</source><year>2005</year><volume>330</volume><fpage>1304</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">15849206</pub-id><pub-id pub-id-type="doi">10.1136/bmj.38415.708634.F7</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowker</surname><given-names>SL</given-names></name><name><surname>Majumdar</surname><given-names>SR</given-names></name><name><surname>Veugelers</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1990</fpage><lpage>1991</lpage><pub-id pub-id-type="pmid">16873829</pub-id><pub-id pub-id-type="doi">10.2337/dc06-0997</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><collab>Adjuvant Breast Cancer Trials Collaborative Group</collab></person-group><article-title>Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">17405995</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djk108</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><year>2000</year><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10647931</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brizel</surname><given-names>DM</given-names></name><name><surname>Rosner</surname><given-names>GL</given-names></name><name><surname>Prosnitz</surname><given-names>LR</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1995</year><volume>32</volume><fpage>1121</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">7607933</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Wencyk</surname><given-names>P</given-names></name><name><surname>Sibbering</surname><given-names>DM</given-names></name><name><surname>Bell</surname><given-names>JA</given-names></name><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Nicholson</surname><given-names>R</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>146</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">7819031</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>RJ</given-names></name><name><surname>Zakikhani</surname><given-names>M</given-names></name><name><surname>Fantus</surname><given-names>IG</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><article-title>Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>10804</fpage><lpage>10812</lpage><pub-id pub-id-type="pmid">18006825</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2310</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurose</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>XP</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Cannistra</surname><given-names>SA</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><article-title>Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas</article-title><source>Am J Pathol</source><year>2001</year><volume>158</volume><fpage>2097</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">11395387</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Hata</surname><given-names>H</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Kamata</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Jobo</surname><given-names>T</given-names></name><name><surname>Kuramoto</surname><given-names>H</given-names></name></person-group><article-title>PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus</article-title><source>J Cancer Res Clin Oncol</source><year>2004</year><volume>130</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">14689303</pub-id><pub-id pub-id-type="doi">10.1007/s00432-003-0517-8</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>N</given-names></name><name><surname>Tokunaga</surname><given-names>C</given-names></name><name><surname>Dalal</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>C</given-names></name><name><surname>Yoshino</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Kemp</surname><given-names>BE</given-names></name><name><surname>Witters</surname><given-names>LA</given-names></name><name><surname>Mimura</surname><given-names>O</given-names></name><name><surname>Yonezawa</surname><given-names>K</given-names></name></person-group><article-title>A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway</article-title><source>Genes Cells</source><year>2003</year><volume>8</volume><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">12558800</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2443.2003.00615.x</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>U</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Hue</surname><given-names>L</given-names></name></person-group><article-title>Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes</article-title><source>Eur J Biochem</source><year>2002</year><volume>269</volume><fpage>3751</fpage><lpage>3759</lpage><pub-id pub-id-type="pmid">12153572</pub-id><pub-id pub-id-type="doi">10.1046/j.1432-1033.2002.03074.x</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horman</surname><given-names>S</given-names></name><name><surname>Browne</surname><given-names>G</given-names></name><name><surname>Krause</surname><given-names>U</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Vertommen</surname><given-names>D</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Lavoinne</surname><given-names>A</given-names></name><name><surname>Hue</surname><given-names>L</given-names></name><name><surname>Proud</surname><given-names>C</given-names></name><name><surname>Rider</surname><given-names>M</given-names></name></person-group><article-title>Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis</article-title><source>Curr Biol</source><year>2002</year><volume>12</volume><fpage>1419</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">12194824</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(02)01077-1</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Fenyk-Melody</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Ventre</surname><given-names>J</given-names></name><name><surname>Doebber</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Musi</surname><given-names>N</given-names></name><name><surname>Hirshman</surname><given-names>MF</given-names></name><name><surname>Goodyear</surname><given-names>LJ</given-names></name><name><surname>Moller</surname><given-names>DE</given-names></name></person-group><article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">11602624</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Gadalla</surname><given-names>AE</given-names></name><name><surname>Olsen</surname><given-names>GS</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name></person-group><article-title>The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>2420</fpage><lpage>2425</lpage><pub-id pub-id-type="pmid">12145153</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.8.2420</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Lamia</surname><given-names>KA</given-names></name><name><surname>Vasquez</surname><given-names>D</given-names></name><name><surname>Koo</surname><given-names>SH</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name><name><surname>Montminy</surname><given-names>M</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><article-title>The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>1642</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">16308421</pub-id><pub-id pub-id-type="doi">10.1126/science.1120781</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guastamacchia</surname><given-names>E</given-names></name><name><surname>Resta</surname><given-names>F</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Schittulli</surname><given-names>F</given-names></name><name><surname>Ciampolillo</surname><given-names>A</given-names></name><name><surname>Triggiani</surname><given-names>V</given-names></name><name><surname>Licchelli</surname><given-names>B</given-names></name><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Sabba</surname><given-names>C</given-names></name><name><surname>Tafaro</surname><given-names>E</given-names></name></person-group><article-title>Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets</article-title><source>Curr Drug Targets Immune Endocr Metabol Disord</source><year>2003</year><volume>3</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">12871027</pub-id><pub-id pub-id-type="doi">10.2174/1568008033340199</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowker</surname><given-names>SL</given-names></name><name><surname>Majumdar</surname><given-names>SR</given-names></name><name><surname>Veugelers</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">16443869</pub-id><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-1558</pub-id></citation></ref></ref-list></back></article> 